Peyona (caffeine citrate) / Chiesi - LARVOL DELTA

COST-EFFECTIVENESS AND BUDGET IMPACT OF CAFFEINE CITRATE VERSUS AMINOPHYLLINE FOR APNEA OF PREMATURITY ACROSS A PUBLIC HEALTHCARE SYSTEM IN MEXICO (ISPOR 2026) - "This study evaluates the cost-effectiveness and budget impact of Peyona® (caffeine citrate; CC) compared with aminophylline for the treatment of apnea of prematurity from the perspective of the ISSSTE in Mexico. A cost-effectiveness analysis combined with a budget impact analysis was conducted from the institutional perspective of ISSSTE. CC represents a cost-effective and cost-saving alternative to aminophylline for the management of apnea of prematurity within ISSSTE, supporting efficient resource allocation and long-term economic sustainability of neonatal care programs."

Cost effectiveness • HEOR • Prematurity

CAPPUCINO-2025: Caffeine administration for preterms in nociception outcomes (clinicaltrialsregister.eu) - P4 | N=200 | Not yet recruiting | Sponsor: Masarykova Univerzita

New P4 trial

The Use of Off-Label Medications in Newborn Infants Despite an Approved Alternative Being Available-Results of a National Survey. (PubMed, Pharmacy (Basel)) - "We investigated the use of the approved formulation or the cheaper off-label alternative of Ibuprofen (Pedea), Propanolol (Hemangiol) and Caffeine Citrate (Peyona) in neonatal clinical practice by conducting a National Survey of 214 Perinatal Centers in Germany. Costs for the three drugs in their approved and marketed formulations increased in median 405-fold compared with the corresponding off-label alternative. Overall, about one out of three neonatologists prescribed an off-label or non-approved drug to patients despite an alternative medication that is approved for the indication in the target population being available."

Journal • Pediatrics

[VIRTUAL] Evaluating efficacy of caffeine for apnea of prematurity in neonatal intensive care unit patients (ASHP 2020) - "Means and standard deviations or medians and ranges, where appropriate, will be used to report continuous variables, whereas, frequencies and percentages will be used to report categorical variables. The student t-test may be used to compare independent samples between the two groups"

Clinical • Atrial Fibrillation • Cardiovascular • Critical care • Heart Failure • Renal Disease

[VIRTUAL] Impact of high dose caffeine on ventilation days in preterm neonates (ASHP 2020) - "Adverse effects of caffeine will be assessed through growth failure, reflux, and dose decreases due to tachycardia, tachypnea, or hypertension. Statistical analysis will include descriptive statistics, independent samples t-test, Chi-Square test and multiple linear regression."

Acute Respiratory Distress Syndrome • Bronchopulmonary Dysplasia • Cardiovascular • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hypertension • Respiratory Diseases • Retinal Disorders • Retinopathy of Prematurity

CAFFEINE TREATMENT IN DELIVERY ROOM FOR VERY PRETERM INFANTS : A FEASIBILITY STUDY TRATTAMENTO DEL NEONATO MOLTO PRETERMINE CON CAFFEINA IN SALA PARTO: STUDIO DI FATTIBILITA’ (clinicaltrialsregister.eu) - P2; N=40; Ongoing; Sponsor: AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI

New P2 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases

[Virtual] Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) Registry (TCT 2020) - "Early data from a multicenter registry demonstrate routine adoption of cangrelor in MI patients with a high proportion of patients receiving a <2 h infusion of cangrelor or a delayed transition to oral P2Y12 inhibition. These real-world findings, a variation from use in clinical trials, show room for optimization of cangrelor use in routine clinical practice."

Clinical • Cardiovascular • Myocardial Infarction